Article Figures & Data
Figures
- FIGURE 1.
Overall detection rate of 18F-rhPSMA-7 PET stratified by PSA value.
- FIGURE 2.
Presence of 18F-rhPSMA-7–avid lesions stratified by PSA value.
- FIGURE 3.
Set of images from 77-y-old patient who underwent radical prostatectomy in 2015 (Gleason score of 9, pT3b, pN1) and was experiencing rising PSA (0.15 ng/mL). (A) Whole-body maximum-intensity projection shows 4 sites with focal PSMA-ligand uptake in pelvis (arrows). (B–G) Axial fused PET/CT and CT images demonstrate local recurrence at anastomosis (B and C, arrow), additional local recurrence at dorsal bladder wall (D and E, arrow), and tiny lymph node metastasis in right pelvis (F and G, arrow). Targeted external-beam radiation treatment lead to subsequent PSA drop.
Tables
Characteristic Data Age at time of scan (y) 72 (49–88) Further treatment External radiation after RP 105 (40) Antihormonal treatment 97 (3) ADT in 6 mo preceding scan 67 (26) Gleason score ≤6 12 (4.6) 7 110 (42) ≥8 87 (33) Unknown 52 (20) Pathologic primary tumor staging at RP pT2 76 (29) pT3 138 (53) pT4 6 (2.3) Unknown 41 (15) Pathologic regional lymph node staging at RP pN0 146 (56) pN1 66 (25) pNx 49 (19) Positive margin at RP R0 94 (36) R1 73 (28) Unknown 94 (36) Initial PSA value (ng/mL) 10.5 (0.09–290) Time between surgery and PET (mo) 56 (0–336) Last PSA value before PET (ng/mL)* 0.961 (0.01–400.0) Injected activity (MBq) 336 (191–417) Uptake time (min) 76 (50–220) ↵* PSA value obtained within 4 wk before 18F-rhPSMA-7 PET examination.
RP = radical prostatectomy.
Qualitative data are expressed as numbers followed by percentages in parentheses; continuous data are expressed as median followed by range in parentheses.
PSA, mean ± SD (ng/mL) P Positive results Negative results 0.004 8.18 ± 39.12 (n = 211) 0.91223 ± 2.06 (n = 50) Metastatic site PSA value (ng/mL) Local recurrence Pelvic lymph nodes Retroperitoneal lymph nodes Supradiaphragmatic lymph nodes Bone Viscera <0.2 4/22 (18%) 3/22 (13.6%) 0/22 (0%) 0/22 (0%) 2/22 (9.1%) 0/22 (0%) 0.2–<0.5 27/59 (46%) 13/59 (22.0%) 4/59 (6.8%) 0/59 (0%) 7/59 (12%) 0/59 (0%) 0.5–<1 21/51 (41%) 19/51 (37.3) 4/51 (7.8%) 1/51 (2.0%) 11/51 (22%) 3/51 (5.9%) 1–<2 22/49 (45%) 24/49 (49.0%) 8/49 (16%) 4/49 (8.2%) 8/49 (16%) 1/49 (2.0%) ≥2 39/80 (49%) 51/80 (63.8%) 29/80 (36%) 16/80 (20.0%) 26/80 (33%) 6/80 (7.5%) All patients 113/261 (43%) 110/261 (42%) 45/261 (17%) 21/261 (8%) 54/261 (21%) 10/261 (4%)
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study
- Unspecific 18F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer
- Validation of 18F-rhPSMA-7 and 18F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer
- Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer
- Utility of 18F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology
- 18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study
- Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
- The Influence of Specific Activity on the Biodistribution of 18F-rhPSMA-7.3: A Retrospective Analysis of Clinical PET Data
- Detection Efficacy of 18F-rhPSMA-7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment
- Combination of Forced Diuresis with Additional Late Imaging in 68Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake
- Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non-Tumor-Related Uptake and Tumor Positivity
- Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T
- Positive Predictive Value and Correct Detection Rate of 18F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard
- Safety, Biodistribution, and Radiation Dosimetry of 18F-rhPSMA-7.3 in Healthy Adult Volunteers
- Histologically Confirmed Diagnostic Efficacy of 18F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer